[Latest] Global PARP Inhibitors Market Size/Share Worth USD 23.5 Billion by 2032 at a 12.1% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)


[220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global PARP Inhibitors Market size & share revenue was valued at approximately USD 7.9 Billion in 2023 and is expected to reach USD 8.4 Billion in 2024 and is expected to reach around USD 23.5 Billion by 2032, at a CAGR of 12.1% between 2024 and 2033. The key market players listed in the report with their sales, revenues and strategies are AstraZeneca plc, GlaxoSmithKline plc, Merck & Co. Inc., Bristol Myers Squibb Company, Pfizer Inc., Johnson & Johnson, AbbVie Inc., Clovis Oncology Inc., Teva Pharmaceutical Industries Ltd., Myriad Genetics Inc., Olympus Corporation, Eisai Co. Ltd., Takeda Pharmaceutical Company Limited, Daiichi Sankyo Company Limited, Zai Lab Limited, and others.

Austin, TX, USA, March 28, 2024 (GLOBE NEWSWIRE) — Custom Market Insights has published a new research report titled PARP Inhibitors Market Size, Trends and Insights By Type (Olaparib, Rucaparib, Niraparib, Talazoparib, Others), By Application (Ovarian Cancer, Breast Cancer, Prostate Cancer, Pancreatic Cancer, Others), By End-User (Hospitals, Clinics, Research Institutes, Others), and By Region – Global Industry Overview, Statistical Data, Competitive Analysis, Share, Outlook, and Forecast 2024–2033 in its research database.

“According to the latest research study, the demand of global PARP Inhibitors Market size & share was valued at approximately USD 7.9 Billion in 2023 and is expected to reach USD 8.4 Billion in 2024 and is expected to reach a value of around USD 23.5 Billion by 2033, at a compound annual growth rate (CAGR) of about 12.1% during the forecast period 2024 to 2033.”


Click Here to Access a Free Sample Report of the Global PARP Inhibitors Market @ https://www.custommarketinsights.com/request-for-free-sample/?reportid=43233

PARP Inhibitors Market: Growth Factors and Dynamics

  • Rising Incidence of BRCA-Mutated Cancers: The increasing prevalence of BRCA-mutated cancers, particularly in breast and ovarian cancer, is a key growth factor for the PARP Inhibitors Market, driving demand for targeted therapies.
  • Expanding Applications: PARP inhibitors find applications beyond breast and ovarian cancers, expanding into prostate, pancreatic, and other cancer types, broadening the market scope and contributing to revenue growth.
  • Advancements in Precision Medicine: The trend towards precision medicine propels the adoption of PARP inhibitors, as these drugs target specific molecular pathways, providing more tailored and effective treatments for cancer patients.
  • Research and Development Investments: Substantial investments in research and development by pharmaceutical companies lead to the discovery of new PARP inhibitors, contributing to an enriched pipeline and a competitive market landscape.
  • Increased Focus on Combination Therapies: The exploration of combination therapies, such as PARP inhibitors with immunotherapies or other targeted agents, represents a dynamic trend, aiming to enhance treatment efficacy and address resistance mechanisms.
  • Expanding Geriatric Population: The aging population is prone to cancers, and as the geriatric demographic expands, there is a growing patient pool for PARP inhibitors, driving market growth and creating opportunities for therapeutic advancements.
  • Clinical Trial Successes: Positive results from clinical trials evaluating the efficacy of PARP inhibitors in various cancer types contribute to market growth. Successful trials validate the therapeutic potential, attract investment, and pave the way for regulatory approvals and expanded indications.
  • Strategic Collaborations and Partnerships: Collaborations between pharmaceutical companies, research institutions, and biotechnology firms drive innovation in the PARP Inhibitors Market. Strategic partnerships facilitate the development of novel drugs and combination therapies, and the exploration of diverse applications, fostering market dynamism and growth.
  • Patient Advocacy and Awareness: Increasing awareness among patients and healthcare professionals about the benefits of PARP inhibitors in cancer treatment is a crucial growth factor. Patient advocacy groups, educational initiatives, and awareness campaigns contribute to higher acceptance and adoption of these targeted therapies.

Request a Customized Copy of the PARP Inhibitors Market Report @ https://www.custommarketinsights.com/inquire-for-discount/?reportid=43233

PARP Inhibitors Market: Partnership and Acquisitions

  • In 2022, Daewon Pharmaceutical introduced Escorten, one of Korea’s initial proton-pump inhibitor drugs. Comprising esomeprazole magnesium trihydrate, Escorten is offered in a 10 mg dosage, providing an effective solution for managing acid-related gastrointestinal conditions and contributing to enhanced patient care in the Korean pharmaceutical market.
  • In 2022, Almac Diagnostic Services has partnered with AstraZeneca to jointly develop and commercialize multiple companion diagnostic (CDx) products. Almac aims to assist AstraZeneca in advancing new therapies globally, particularly in disease areas with significant unmet medical needs, fostering advancements in patient care.
  • In 2023, MedGenome introduced a genetic test for Facioscapulohumeral Muscular Dystrophy diagnosis in India, broadening its product portfolio. The move reflects escalating competition in the market, highlighting the company’s commitment to addressing unmet medical needs and expanding its presence in the genetic testing sector.

Report Scope

Feature of the Report Details
Market Size in 2024 USD 8.4 Billion
Projected Market Size in 2033 USD 23.5 Billion
Market Size in 2023 USD 7.9 Billion
CAGR Growth Rate 12.1% CAGR
Base Year 2023
Forecast Period 2024-2033
Key Segment By Type, Application, End-User and Region
Report Coverage Revenue Estimation and Forecast, Company Profile, Competitive Landscape, Growth Factors and Recent Trends
Regional Scope North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America
Buying Options Request tailored purchasing options to fulfil your requirements for research.

(A free sample of the PARP Inhibitors report is available upon request; please contact us for more information.)

Our Free Sample Report Consists of the following:

  • Introduction, Overview, and in-depth industry analysis are all included in the 2023 updated report.
  • The COVID-19 Pandemic Outbreak Impact Analysis is included in the package.
  • About 220+ Pages Research Report (Including Recent Research)
  • Provide detailed chapter-by-chapter guidance on the Request.
  • Updated Regional Analysis with a Graphical Representation of Size, Share, and Trends for the Year 2023
  • Includes Tables and figures have been updated.
  • The most recent version of the report includes the Top Market Players, their Business Strategies, Sales Volume, and Revenue Analysis 
  • Custom Market Insights (CMI) research methodology

(Please note that the sample of the PARP Inhibitors report has been modified to include the COVID-19 impact study prior to delivery.)

Request a Customized Copy of the PARP Inhibitors Market Report @ https://www.custommarketinsights.com/report/parp-inhibitors-market/

PARP Inhibitors Market: COVID-19 Analysis

The COVID-19 pandemic has had a significant impact on the PARP Inhibitors Market, with the industry experiencing both positive and negative effects. Here are some of the key impacts:

  • Disruption in Clinical Trials: The pandemic led to disruptions in ongoing clinical trials for PARP inhibitors, causing delays in research and development timelines.
  • Shift in Healthcare Priorities: COVID-19 prompted a shift in healthcare priorities, with resources diverted towards managing the pandemic, impacting patient access to cancer treatments, including PARP inhibitors.
  • Resumption of Clinical Trials: As the healthcare sector adapted to the pandemic, there was a gradual resumption of clinical trials for PARP inhibitors, accelerating research and development activities.
  • Telehealth Adoption: Increased adoption of telehealth solutions facilitated continued patient care, including consultations and monitoring for PARP inhibitor treatments, supporting ongoing and new patient engagements.
  • Government Initiatives and Funding: Government initiatives and funding for cancer research and treatment contributed to the recovery, ensuring sustained support for the development and accessibility of PARP inhibitors.
  • Patient Education and Awareness Programs: Initiatives focused on patient education and awareness regarding the importance of continued cancer treatment, including PARP inhibitors, helped rebuild confidence among patients, encouraging their adherence to treatment plans.
  • Flexible Treatment Options: The pandemic emphasized the need for flexible treatment options. PARP inhibitors, with their oral administration, offered a more adaptable treatment approach, allowing patients to continue therapy with reduced hospital visits and mitigating the impact of pandemic-related restrictions.
  • Global Collaboration for Supply Chain Resilience: Collaborations and strategic partnerships across borders aimed at building a resilient supply chain for pharmaceuticals, including PARP inhibitors, helped ensure a consistent and uninterrupted supply of these critical cancer therapies, contributing to market recovery.
  • Healthcare Reimbursement Policies: Favorable healthcare reimbursement policies for PARP inhibitors, especially in developed markets, incentivize healthcare providers to prescribe these drugs. Improved access to reimbursement aligns with market growth, ensuring that patients have affordable access to these advanced and effective cancer treatments.

In conclusion, the COVID-19 pandemic has had a mixed impact on the PARP Inhibitors Market, with some challenges and opportunities arising from the pandemic.

Request a Customized Copy of the PARP Inhibitors Market Report @ https://www.custommarketinsights.com/report/parp-inhibitors-market/

Key questions answered in this report:

  • What is the size of the PARP Inhibitors market and what is its expected growth rate?
  • What are the primary driving factors that push the PARP Inhibitors market forward?
  • What are the PARP Inhibitors Industry’s top companies?
  • What are the different categories that the PARP Inhibitors Market caters to?
  • What will be the fastest-growing segment or region?
  • In the value chain, what role do essential players play?
  • What is the procedure for getting a free copy of the PARP Inhibitors market sample report and company profiles?

Key Offerings:

  • Market Share, Size & Forecast by Revenue | 2023−2032
  • Market Dynamics – Growth Drivers, Restraints, Investment Opportunities, and Leading Trends
  • Market Segmentation – A detailed analysis by Types of Services, by End-User Services, and by regions
  • Competitive Landscape – Top Key Vendors and Other Prominent Vendors

Buy this Premium PARP Inhibitors Research Report | Fast Delivery Available – [220+ Pages] @ https://www.custommarketinsights.com/report/parp-inhibitors-market/

PARP Inhibitors Market – Regional Analysis

The PARP Inhibitors Market is segmented into various regions, including North America, Europe, Asia-Pacific, and LAMEA. Here is a brief overview of each region:

  • North America: In North America, a prominent trend in the PARP Inhibitors Market is the integration of genomic testing into mainstream oncology practices. Advanced healthcare infrastructure and increased awareness drive this trend, facilitating widespread genetic screening for mutations and subsequent targeted treatment with PARP inhibitors.
  • Europe: Europe exhibits a trend of collaborative initiatives between pharmaceutical companies and academic institutions. Strategic partnerships and joint research efforts enhance the development of PARP inhibitors. This collaborative approach aims to accelerate clinical trials, expand treatment indications, and optimize the use of PARP inhibitors in diverse cancer types.
  • Asia-Pacific: In the Asia-Pacific region, a noteworthy trend is the emphasis on real-world evidence generation. Efforts focus on accumulating data on the effectiveness and safety of PARP inhibitors in diverse patient populations. This trend aligns with the region’s diverse genetic profiles and supports evidence-based decision-making in the adoption of PARP inhibitors.
  • Latin America, Middle East, and Africa (LAMEA): LAMEA showcases a trend of increasing accessibility to PARP inhibitors through regional collaborations. Efforts include partnerships between pharmaceutical companies, healthcare organizations, and governments to improve affordability, distribution networks, and awareness, ensuring broader access to these precision cancer therapies in the LAMEA region.

Request a Customized Copy of the PARP Inhibitors Market Report @ https://www.custommarketinsights.com/report/parp-inhibitors-market/

(We customized your report to meet your specific research requirements. Inquire with our sales team about customizing your report.)

Still, Looking for More Information? Do OR Want Data for Inclusion in magazines, case studies, research papers, or Media 

Email Directly Here with Detail Information: [email protected]

Browse the full PARP Inhibitors Market Size, Trends and Insights By Type (Olaparib, Rucaparib, Niraparib, Talazoparib, Others), By Application (Ovarian Cancer, Breast Cancer, Prostate Cancer, Pancreatic Cancer, Others), By End-User (Hospitals, Clinics, Research Institutes, Others), and By Region – Global Industry Overview, Statistical Data, Competitive Analysis, Share, Outlook, and Forecast 2024–2033 Report at https://www.custommarketinsights.com/report/parp-inhibitors-market/

List of the prominent players in the PARP Inhibitors Market:

  • AstraZeneca plc
  • GlaxoSmithKline plc
  • Merck & Co. Inc.
  • Bristol Myers Squibb Company
  • Pfizer Inc.
  • Johnson & Johnson
  • AbbVie Inc.
  • Clovis Oncology Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Myriad Genetics Inc.
  • Olympus Corporation
  • Eisai Co. Ltd.
  • Takeda Pharmaceutical Company Limited
  • Daiichi Sankyo Company Limited
  • Zai Lab Limited
  • Others

Click Here to Access a Free Sample Report of the Global PARP Inhibitors Market @ https://www.custommarketinsights.com/report/parp-inhibitors-market/

Spectacular Deals

  • Comprehensive coverage
  • Maximum number of market tables and figures
  • The subscription-based option is offered.
  • Best price guarantee
  • Free 35% or 60 hours of customization.
  • Free post-sale service assistance.
  • 25% discount on your next purchase.
  • Service guarantees are available.
  • Personalized market brief by author.

Browse More Related Reports: 

Lung Cancer Screening Software Market: Lung Cancer Screening Software Market Size, Trends and Insights By Mode of Delivery (Cloud Based Solutions, On-Premise Solutions, Web Based Solutions), By Product (Lung Cancer Screening Radiology Solution, Lung Cancer Screening Patient Management Software, Nodule Management Software, Data Collection and Reporting, Patient Coordination and Workflow, Lung Nodule Computer Aided Detection, Pathology and Cancer Staging, Statistical Audit Reporting, Screening PACS, Practice Management, Audit Log Tracking), By Type (Computer-Assisted Screening, Traditional Screening), By Application (Non-Small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC)), By Platform (Standalone, Integrated), By Purchase Mode (Institutional, Individual), By End User (Oncology Centers, Hospitals, Ambulatory Surgical Centers, Others), By Distribution Channel (Direct Tender, Third Party Distributors), and By Region – Global Industry Overview, Statistical Data, Competitive Analysis, Share, Outlook, and Forecast 2024–2033

Cancer Monoclonal Antibodies Market: Cancer Monoclonal Antibodies Market Size, Trends and Insights By Type (Humanized, Human, Chimeric, Murine), By Application (Blood Cancer, Breast Cancer, Lung Cancer, Melanoma, Colorectal Cancer, Liver Cancer, Others), By Monoclonal Antibody Therapies (Bevacizumab (Avastin), Rituximab (Rituxan), Trastuzumab (Herceptin), Cetuximab (Erbitux), Panitumumab (Vectibix), Other Monoclonal Antibody Therapies), By End-User (Hospitals, Research Institutes, Others), and By Region – Global Industry Overview, Statistical Data, Competitive Analysis, Share, Outlook, and Forecast 2024–2033

Liver Cancer Diagnostics Market: Liver Cancer Diagnostics Market Size, Trends and Insights By Test Type (AFP Tests, LFTs, Biopsy, Others), By End-User (Hospital-associated Labs, Independent Diagnostic Laboratories, Cancer Research Institutes, Others), and By Region – Global Industry Overview, Statistical Data, Competitive Analysis, Share, Outlook, and Forecast 2024–2033

Anal Cancer Market: Anal Cancer Market Size, Trends and Insights By Drug Type (Fluorouracil, Cisplatin, Carboplatin, Others), By Cancer Type (Carcinoma In-situ, Squamous Cell Carcinoma, Melanoma, Adenocarcinoma, Basal Cell Carcinoma), By Treatment Type (Chemotherapy, Surgery, Radiation Therapy, Immunotherapy), By Distribution Channel (Hospitals & Clinics, Research & Academic Institutes, Long-term Care Centers, Pharmacies), and By Region – Global Industry Overview, Statistical Data, Competitive Analysis, Share, Outlook, and Forecast 2024–2033

Lung Cancer Surgery Market: Lung Cancer Surgery Market Size, Trends and Insights By Product (Thoracoscopes, Mediastinoscopes, Bronchoscopes, Robotic-Assisted Thoracic Surgery Systems, Surgical Staplers, Surgical Energy Instruments), By Application (Lobectomy, Segmentectomy, Wedge Resection, Pneumonectomy), By End-User (Hospitals, Ambulatory Surgical Centers), and By Region – Global Industry Overview, Statistical Data, Competitive Analysis, Share, Outlook, and Forecast 2024–2033

Lung Tumor Market: Lung Tumor Market Size, Trends and Insights By Product (Imaging systems, Biopsy needles and devices, Surgical instruments, Radiation therapy equipment, Chemotherapy drugs, Targeted therapies, Immunotherapy drugs), By Application (Early Detection, Diagnosis, Treatment, Prognosis), By End-User (Hospitals and clinics, Cancer centers, Imaging centers, Research institutions), and By Region – Global Industry Overview, Statistical Data, Competitive Analysis, Share, Outlook, and Forecast 2024–2033

The PARP Inhibitors Market is segmented as follows:

By Type

  • Olaparib
  • Rucaparib
  • Niraparib
  • Talazoparib
  • Others

By Application

  • Ovarian Cancer
  • Breast Cancer
  • Prostate Cancer
  • Pancreatic Cancer
  • Others

By End-User

  • Hospitals
  • Clinics
  • Research Institutes
  • Others

Click Here to Get a Free Sample Report of the Global PARP Inhibitors Market @ https://www.custommarketinsights.com/report/parp-inhibitors-market/

Regional Coverage:

North America

  • U.S.
  • Canada
  • Mexico
  • Rest of North America


  • Germany
  • France
  • U.K.
  • Russia
  • Italy
  • Spain
  • Netherlands
  • Rest of Europe

Asia Pacific

  • China
  • Japan
  • India
  • New Zealand
  • Australia
  • South Korea
  • Taiwan
  • Rest of Asia Pacific

The Middle East & Africa

  • Saudi Arabia
  • UAE
  • Egypt
  • Kuwait
  • South Africa
  • Rest of the Middle East & Africa

Latin America

  • Brazil
  • Argentina
  • Rest of Latin America

This PARP Inhibitors Market Research/Analysis Report Contains Answers to the following Questions.

  • Which Trends Are Causing These Developments?
  • Who Are the Global Key Players in This PARP Inhibitors Market? What are Their Company Profile, Product Information, and Contact Information?
  • What Was the Global Market Status of the PARP Inhibitors Market? What Was the Capacity, Production Value, Cost and PROFIT of the PARP Inhibitors Market?
  • What Is the Current Market Status of the PARP Inhibitors Industry? What’s Market Competition in This Industry, Both Company and Country Wise? What’s Market Analysis of PARP Inhibitors Market by Considering Applications and Types?
  • What Are Projections of the Global PARP Inhibitors Industry Considering Capacity, Production and Production Value? What Will Be the Estimation of Cost and Profit? What Will Be Market Share, Supply and Consumption? What about imports and exports?
  • What Is PARP Inhibitors Market Chain Analysis by Upstream Raw Materials and Downstream Industry?
  • What Is the Economic Impact On PARP Inhibitors Industry? What are Global Macroeconomic Environment Analysis Results? What Are Global Macroeconomic Environment Development Trends?
  • What Are Market Dynamics of PARP Inhibitors Market? What Are Challenges and Opportunities?
  • What Should Be Entry Strategies, Countermeasures to Economic Impact, and Marketing Channels for PARP Inhibitors Industry?

Click Here to Access a Free Sample Report of the Global PARP Inhibitors Market @ https://www.custommarketinsights.com/report/parp-inhibitors-market/ 

Reasons to Purchase PARP Inhibitors Market Report

  • PARP Inhibitors Market Report provides qualitative and quantitative analysis of the market based on segmentation involving economic and non-economic factors.
  • PARP Inhibitors Market report outlines market value (USD) data for each segment and sub-segment.
  • This report indicates the region and segment expected to witness the fastest growth and dominate the market.
  • PARP Inhibitors Market Analysis by geography highlights the consumption of the product/service in the region and indicates the factors affecting the market within each region.
  • The competitive landscape incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled.
  • Extensive company profiles comprising company overview, company insights, product benchmarking, and SWOT analysis for the major market players.
  • The Industry’s current and future market outlook concerning recent developments (which involve growth opportunities and drivers as well as challenges and restraints of both emerging and developed regions.
  • PARP Inhibitors Market Includes in-depth market analysis from various perspectives through Porter’s five forces analysis and provides insight into the market through Value Chain.

Reasons for the Research Report

  • The study provides a thorough overview of the global PARP Inhibitors market. Compare your performance to that of the market as a whole.
  • Aim to maintain competitiveness while innovations from established key players fuel market growth.

Buy this Premium PARP Inhibitors Research Report | Fast Delivery Available – [220+ Pages] @ https://www.custommarketinsights.com/report/parp-inhibitors-market/

What does the report include?

  • Drivers, restrictions, and opportunities are among the qualitative elements covered in the worldwide PARP Inhibitors market analysis.
  • The competitive environment of current and potential participants in the PARP Inhibitors market is covered in the report, as well as those companies’ strategic product development ambitions.
  • According to the component, application, and industry vertical, this study analyzes the market qualitatively and quantitatively. Additionally, the report offers comparable data for the important regions.
  • For each segment mentioned above, actual market sizes and forecasts have been given.

Who should buy this report?

  • Participants and stakeholders worldwide PARP Inhibitors market should find this report useful. The research will be useful to all market participants in the PARP Inhibitors industry.
  • Managers in the PARP Inhibitors sector are interested in publishing up-to-date and projected data about the worldwide PARP Inhibitors market.
  • Governmental agencies, regulatory bodies, decision-makers, and organizations want to invest in PARP Inhibitors products’ market trends.
  • Market insights are sought for by analysts, researchers, educators, strategy managers, and government organizations to develop plans. 

Request a Customized Copy of the PARP Inhibitors Market Report @ https://www.custommarketinsights.com/report/parp-inhibitors-market/

About Custom Market Insights:

Custom Market Insights is a market research and advisory company delivering business insights and market research reports to large, small, and medium-scale enterprises. We assist clients with strategies and business policies and regularly work towards achieving sustainable growth in their respective domains.

CMI provides a one-stop solution for data collection to investment advice. The expert analysis of our company digs out essential factors that help to understand the significance and impact of market dynamics. The professional experts apply clients inside on the aspects such as strategies for future estimation fall, forecasting or opportunity to grow, and consumer survey.

Follow Us: LinkedIn | Twitter | Facebook | YouTube

Contact Us:

Joel John

CMI Consulting LLC

1333, 701 Tillery Street Unit 12,

Austin, TX, Travis, US, 78702

USA: +1 801-639-9061

India: +91 20 46022736

Email: [email protected]

Web: https://www.custommarketinsights.com/

Blog: https://www.techyounme.com/

Blog: https://atozresearch.com/

Blog: https://www.technowalla.com/

Blog: https://marketresearchtrade.com/

Buy this Premium PARP Inhibitors Research Report | Fast Delivery Available – [220+ Pages] @ https://www.custommarketinsights.com/report/parp-inhibitors-market/

Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. AfternoonHeadlines.com takes no editorial responsibility for the same.